All In MedTech

Device Trial Radar · NCT03395522

Study to Assess the Efficacy of the iTind in Subjects With Symptomatic BPH

One-arm, Multi-center, International Prospective Study to Assess the Efficacy of Medi-tate Temporary Implantable Nitinol Device (iTind) in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

149

Actual

Start

Feb 18, 2018

Primary completion

Jun 18, 2023

Study completion Apr 25, 2025

Sponsor

Lead sponsor
Medi-Tate Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Jan 10, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A total of up to 200 Symptomatic BPH subjects subjects will be enrolled into the study. Study duration will be 12 months post implantation with a follow-up visits at Year 2 and Year 3.

Conditions

  • BPH

Interventions

  • iTindDevice

    device implanted for 5-7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. IPSS (International Prostate Symptoms Score) Responders RateTime frame: at Month 6 Visit

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • Sydney Adventist Hospital Clinical School of the University of Sydney

    Sydney, Australia

  • Hospital Center University De Bordeaux

    Bordeaux, France

  • Hôpital Cochin

    Paris, France

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.